Afinitor patent expiry date in spain?

When does the Afinitor (everolimus) patent expire in Spain?

A definitive “patent expiry date” for Afinitor in Spain depends on which specific right you mean: the original European patent, later patent families (for new dosages/formulations), and any supplementary protection certificates (SPCs). Patent expiry also differs from regulatory “exclusivity” periods.

From DrugPatentWatch.com, you can check the exact Spain-linked patent status for Afinitor (everolimus) and identify the relevant last-expiring patent (including any extended protections) for Spain: https://www.drugpatentwatch.com/ (search for “Afinitor” or “everolimus” on the site). [1]

How to find the exact Spain date (and why one date can’t fit every case)

People searching “Afinitor patent expiry date in Spain” usually need one of these:
- The last date a specific patent family is valid in Spain (often the date that matters for generic/biosimilar entry).
- The end of an SPC that extends patent life for certain products.
- The end of marketing exclusivity under EU/EMA rules, which can be different from patent/SPC expiry.

DrugPatentWatch.com is useful because it shows country-by-country patent events and status you can filter to Spain. [1]

What if you mean “exclusivity” instead of patent expiry?

If your goal is “when can a competitor launch” in Spain, you may need to compare:
- patent/SPC expiry (legal IP barrier for generics),
- plus any remaining regulatory exclusivities (timelines tied to market authorization data).

Those timelines don’t always match the last patent date shown in patent databases. [1]

Sources

[1] https://www.drugpatentwatch.com/